Company intelligence / Profile preview

Bonus BioGroup

Ownership: Private
Development stage: Phase 2

Overview

The company has completed Phase II clinical trials for MesenCure for treating ARDS and received FDA clearance for Phase III clinical study in the United States. BonoFill is in Phase II/III clinical trials for bone defects.

Therapeutic areas: OtherPulmonology
Modalities: Cell therapyTissue engineering
Industry: Biotech

Drug pipeline

3 assets

MesenCure

2 more assets in the full pipeline.

Partnerships

Israel Institute for Biological ResearchThe Jackson Laboratory USASt. Catherine's Hospital in Zagreb

Beyond the preview

Go deeper on Bonus BioGroup.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bonus BioGroup.